Know Cancer

forgot password

A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

Phase 2
18 Years
Not Enrolling

Thank you

Trial Information

A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus


- Determine the antitumor activity of dacarbazine, mitomycin, doxorubicin, and cisplatin
plus sargramostim (GM-CSF) in patients with advanced, persistent, or recurrent
leiomyosarcoma of the uterus.

- Determine the nature and degree of toxicity of this regimen in these patients.

OUTLINE: Patients receive dacarbazine IV over 2 hours, followed by mitomycin IV over 2-5
minutes, doxorubicin IV over 2-5 minutes, and cisplatin IV over 2 hours on day 1. Patients
also receive sargramostim (GM-CSF) subcutaneously (SC) once every 12 hours on days -6 to -3
before the first chemotherapy course and then on days 2-15 and 23-26 of all chemotherapy
courses. Courses repeat every 28 days in the absence of disease progression or unacceptable
toxicity. Patients achieving stable disease receive a maximum of 4 courses. Patients
achieving complete or partial response receive a maximum of 6 courses.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.

PROJECTED ACCRUAL: A total of 12-43 patients will be accrued for this study within 12-28

Inclusion Criteria


- Histologically confirmed primary leiomyosarcoma (LMS) of the uterus

- Advanced, persistent, or recurrent disease that is refractory to curative
therapy or established treatments

- At least 1 unidimensionally measurable target lesion

- At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT
scan, or MRI) OR

- At least 10 mm by spiral CT scan

- Tumors within a previously irradiated field are designated as non-target lesions

- Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists),
including any active phase III protocol for the same population



- 18 and over

Performance status:

- GOG 0-2

Life expectancy:

- Not specified


- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3


- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 2.5 times ULN

- Alkaline phosphatase no greater than 2.5 times ULN


- Creatinine no greater than 1.5 times ULN


- No active infection requiring antibiotics

- No grade 2 or greater sensory or motor neuropathy

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer


Biologic therapy:

- Not specified


- No prior cytotoxic chemotherapy for LMS of the uterus

Endocrine therapy:

- At least 1 week since prior hormonal therapy for LMS of the uterus

- Concurrent hormone replacement therapy allowed


- See Disease Characteristics

- Recovered from prior recent radiotherapy


- Recovered from prior recent surgery


- Recovered from other prior recent therapy

- No prior cancer treatment that would preclude study therapy

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Harry J. Long, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Mayo Clinic


United States: Federal Government

Study ID:




Start Date:

March 2002

Completion Date:

Related Keywords:

  • Sarcoma
  • stage IV uterine sarcoma
  • recurrent uterine sarcoma
  • uterine leiomyosarcoma
  • Leiomyosarcoma
  • Uterine Neoplasms
  • Sarcoma



Mayo Clinic Cancer Center Rochester, Minnesota  55905
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
University of Colorado Cancer Center Denver, Colorado  80262
Walter Reed Army Medical Center Washington, District of Columbia  20307-5000
Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois  60612
Washington University School of Medicine Saint Louis, Missouri  63110
State University of New York Health Sciences Center - Stony Brook Stony Brook, New York  11790-7775
Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina  27599-7295
Duke Comprehensive Cancer Center Durham, North Carolina  27710
University of Oklahoma College of Medicine Oklahoma City, Oklahoma  73190
Abington Memorial Hospital Abington, Pennsylvania  19001
University of Pennsylvania Cancer Center Philadelphia, Pennsylvania  19104
Tacoma General Hospital Tacoma, Washington  98405
Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina  27157-1082
University of Texas Medical Branch Galveston, Texas  77555-1329
Holden Comprehensive Cancer Center Iowa City, Iowa  52242-1009
Tuft-New England Medical Center Boston, Massachusetts  02111
Cooper University Hospital Camden, New Jersey  08103
Barrett Cancer Center Cincinnati, Ohio  45267-0502
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland  20892-1182